June 17, 2020 / 11:46 AM / 19 days ago

BRIEF-Kamada Announces Availability Of Its Plasma-Derived Hyperimmune IgG Therapy For COVID-19 For Compassionate Use Treatment In Israel

June 17 (Reuters) - Kamada Ltd:

* KAMADA LTD - ANNOUNCES AVAILABILITY OF ITS PLASMA-DERIVED HYPERIMMUNE IGG THERAPY FOR COVID-19 FOR COMPASSIONATE USE TREATMENT IN ISRAEL

* KAMADA LTD - INTENDS TO INITIATE A PHASE 1/2 CLINICAL STUDY IN HOSPITALIZED COVID-19 PATIENTS IN ISRAEL DURING Q3

* KAMADA LTD - CO, KEDRION EXPANDING CLINICAL DEVELOPMENT PROGRAM TO U.S. AND EXPECT TO HOLD A PRE-IND MEETING WITH FDA EARLY IN Q3

* KAMADA LTD - INTENDS TO MANUFACTURE FUTURE BATCHES USING U.S. COVID-19 CONVALESCENT PLASMA COLLECTED BY KEDRION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below